Neuralink has moved to validate its controversial brain-implant technology in the scientific arena by submitting its first study for peer review and publication.
The rapidly expanding brain-computer interface (BCI) field is not only driving cutting-edge neuroscience but also fueling a competitive race for market dominance.
Apple is reportedly working with brain-computer interface (BCI) company Synchron to develop technology that allows users to control their iPhones and other Apple devices using their minds.
Several U.S. Food and Drug Administration (FDA) employees, including some involved in reviewing Elon Musk’s Neuralink, have been fired or released recently. Now, the FDA wants them back.
Neuralink, Elon Musk’s brain-computer interface (BCI) company, has received the FDA's “breakthrough device” designation for its innovative 'Blindsight' implant.
Synchron, a competitor to Neuralink, has announced one of its patients with ALS is now able to control devices using only his mind with its brain chip implant.
Neuralink has implanted its experimental N1 brain-computer interface (BCI) within a second patient, with Elon Musk, the company's CEO, saying the procedure is “working very well.”
Neuralink recently revealed that it chose to postpone the insertion of a second brain chip implant in a procedure that had been eagerly anticipated by the medical and tech communities.
The FDA has approved Elon Musk's Neuralink to implant its experimental brain chip technology in a second individual, following issues that arose with its first patient.